Lilly To Partner With Indian Drug Makers In Wake Of Patent Protection (India)
This article was originally published in PharmAsia News
Eli Lilly is engaging in joint ventures with Indian pharmaceuticals to take advantage of their move to research and development and away from generics. U.S.-based Lilly's CEO said his company is interested in getting involved in global trials with companies that develop their own drugs as far as the Phase III stage. Sidney Taurel also said India's adoption of new patent protections is welcomed by firms such as his. Among companies Taurel mentioned were Jubilant Biosys, Nicholas Piramal India and Suven Pharmaceuticals. (Click here for more
You may also be interested in...
Wave’s Duchenne muscular dystrophy drug and Lilly’s chronic pain R&D will test the agency’s CID meeting pilot program, while FDA issues draft guidance that highlights potential uses for complex innovative trial designs.
Agency officials can now discuss the ideas that have been accepted, though not in great detail.
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.